PIM kinase inhibition in HCC xenograft

Human HCC cell line, MHCC-97L, was subcutaneously injected to BALB/c nude mice. Two weeks post injection, mice were randomised to receive vehicle or PIM447 (60mg/kg) by oral gavage three times a week for two weeks. Total RNA was extracted from the tumor xenograft (Vehicle, n=2; PIM447, n=2) and subjected to RNA sequencing. Expression profiling of the tumors between vehicle control and PIM447 treated groups was compared. Overall design: Total RNA extracted from tumor xenograft of mice treated with vehicle (n=2) and PIM447 (n=2) were subjected to RNA sequencing profiling.